China's self-developed antitumor drug Sintilimab Injection was granted approval for market authorization by the National Medical Products Administration of China for the treatment of patients with Hodgkin's Lymphoma.
Hodgkin's lymphoma is a cancer in part of the body's immune system -- the lymphatic system.
The disease may affect people of any age, but is the most common in people between 20 and 40 years old and those over 55.
According to the Lancet, a world's leading independent general medical journal, standard chemotherapy or combined-modality therapy is highly effective for treatment of this disease, and most patients can be cured.
Researchers are also working on over 20 types of clinical trials in an effort to extend the use of Sintilimab Injection to cover other types of cancer such as lung cancer and liver cancer.
